Clinical Trials Browser

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT01920932 2026-05-06

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2 Active not recruiting

77 enrolled 20 charts

Lymphoid

Hodgkin Disease, Neoplasms

NCT03217747 2026-05-05

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02180867 2026-05-04

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Phase 2/3 Active not recruiting

140 enrolled 22 charts

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Granuloma, Plasma Cell, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Chondrosarcoma, Mesenchymal, Dermatofibrosarcoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Perivascular Epithelioid Cell Neoplasms

NCT02883049 2026-05-04

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Phase 3 Active not recruiting

5,949 enrolled 28 charts

Lymphoid

Burkitt Lymphoma

NCT03907488 2026-05-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 1 FDA

Lymphoid

Hodgkin Disease

NCT03228537 2026-05-01

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Phase 1 Active not recruiting

28 enrolled 17 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT02595879 2026-04-29

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Phase 1 Active not recruiting

21 enrolled 22 charts

Gynecologic

Uterine Cervical Neoplasms

NCT04460937 2026-04-29

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Phase 1 Active not recruiting

4 enrolled 9 charts

CNSGastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Brain Neoplasms, Meningeal Carcinomatosis

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT01507428 2026-04-21

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

Phase 2 Completed

138 enrolled 42 charts

Stage III Lung Non-Small Cell Cancer AJCC v7

NCT02917421 2026-04-17

ART

Phase 1/2 Active not recruiting

88 enrolled 10 charts

Breast

Breast Neoplasms

NCT02466971 2026-04-13

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3 Active not recruiting

450 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03786783 2026-04-13

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2 Active not recruiting

42 enrolled 12 charts

CNS

Ganglioneuroblastoma

NCT01706939 2026-04-09

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

Phase 3 Active not recruiting

23 enrolled 19 charts

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Phase 2 Active not recruiting

52 enrolled 19 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01266642 2026-03-11

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Phase 2 Active not recruiting

301 enrolled 9 charts

Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

EndocrineNET

Neuroendocrine Tumors

Clinical Trials

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

TAILORx

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Morpheus Lung

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

ART

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer